Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dinutuximab + Expanded gamma delta T-cells + Irinotecan + Temozolomide + Zoledronic acid |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dinutuximab | Unituxin | MOAB Ch14.18 | Unituxin (dinutuximab) is a monoclonal antibody that targets B4GALNT1 (GD2) and increases antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells (PMID: 26917818). Unituxin (dinutuximab) is FDA approved for pediatric high-risk neuroblastoma (FDA.gov). | |
Expanded gamma delta T-cells | Ex vivo-expanded allogeneic gamma 9 delta 2 T-cells | Expanded gamma delta T-cells are gamma delta T-cells expanded from allogeneic peripheral blood mononuclear cells stimulated with IL-2 and zoledronate, which may induce tumor cell killing and inhibit tumor growth (PMID: 35371623). | ||
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Zoledronic acid | Zometa | zoledronate |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05400603 | Phase I | Dinutuximab + Expanded gamma delta T-cells + Irinotecan + Temozolomide + Zoledronic acid | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (Aflac-NBL-2002) | Recruiting | USA | 0 |